12-Year Outcomes Following Permanent Prostate Brachytherapy in Patients with Clinically Localized Prostate Cancer

2008346 citationsJournal Article

Authors

Louis Potters · Mercy Medical Center

C. Morgenstern · South Nassau Communities Hospital

Emil Calugaru · South Nassau Communities Hospital

Paul Fearn · Mercy Medical Center

Anup Jassal · South Nassau Communities Hospital

Joseph Presser · South Nassau Communities Hospital

E.E. Mullen

Abstract

PPB offers acceptable 12-year BFR in patients who present with clinically localized prostate cancer. Implant dosimetry continues as an important predictor for BFR, while the addition of adjuvant therapies such as hormones and external radiation are insignificant. In patients who experience biochemical failure it appears that PSA doubling time is an important predictor of survival.

Topics & Keywords

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Advanced Radiotherapy Techniques

UN Sustainable Development Goals

Peace, Justice and strong institutions

Publication Details

Published in: The Journal of Urology

Volume 179, Issue 5S, pp. S20-4

DOI: 10.1016/j.juro.2008.03.133

Field-Weighted Citation Impact: 30.01